DENALI THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.26 USD | -3.99% |
|
-4.84% | -10.25% |
Financials (USD)
| Sales 2024 * | 46.94M | Sales 2025 * | 106M | Capitalization | 2.75B |
|---|---|---|---|---|---|
| Net income 2024 * | -425M | Net income 2025 * | -460M | EV / Sales 2024 * | 31.8 x |
| Net cash position 2024 * | 1.25B | Net cash position 2025 * | 1.05B | EV / Sales 2025 * | 16 x |
| P/E ratio 2024 * |
-7.05
x | P/E ratio 2025 * |
-7.08
x | Employees | 375 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.32% |
More Fundamentals
* Assessed data
More news
Latest transcript on Denali Therapeutics Inc.
More recommendations
More press releases
More news
| 1 day | -3.99% | ||
| 1 week | -4.84% | ||
| Current month | +24.74% | ||
| 1 month | +19.55% | ||
| 3 months | +13.76% | ||
| 6 months | +6.41% | ||
| Current year | -10.25% |
1 week
18.89
20.72
1 month
14.5620.91
Current year
14.5623.52
1 year
14.5633.31
3 years
14.5679.70
5 years
12.3993.94
10 years
12.3293.94
| Managers | Title | Age | Since |
|---|---|---|---|
Alexander Schuth
FOU | Founder | 50 | 13-10-13 |
Ryan Watts
FOU | Founder | 48 | 13-10-13 |
Joe Lewcock
CTO | Chief Tech/Sci/R&D Officer | - | 19-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Vicki Sato
CHM | Chairman | 75 | 15-03-31 |
Jay Flatley
BRD | Director/Board Member | 71 | 15-03-31 |
David Schenkein
BRD | Director/Board Member | 66 | 15-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.31% | 0 M€ | 0.00% | - | |
| 0.31% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-23 | 19.26 | -3.99% | 1,019,323 |
| 24-05-22 | 20.06 | +0.40% | 753,631 |
| 24-05-21 | 19.98 | -0.75% | 558,759 |
| 24-05-20 | 20.13 | -1.85% | 856,057 |
| 24-05-17 | 20.51 | +1.33% | 750,216 |
Delayed Quote Nasdaq, May 23, 2024 at 04:00 pm EDT
More quotes
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinsonâs disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS). In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome).
Calendar
2024-05-31
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
19.26
USD
Average target price
38.67
USD
Spread / Average Target
+100.76%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.25% | 2.75B | |
| +10.79% | 116B | |
| +11.65% | 106B | |
| -6.20% | 23.89B | |
| -2.33% | 21.58B | |
| -6.03% | 18.96B | |
| -13.41% | 16.33B | |
| -40.50% | 16.96B | |
| +6.64% | 14.14B | |
| +31.84% | 12.02B |
- Stock Market
- Equities
- DNLI Stock
